Pharma BD Deal Intelligence
Up-to-$1.2B neurodegenerative disease collaboration launched by Takeda, Denali. Denali receives $40 million upfront and $110 million equity investment.
Takeda and Denali Therapeutics collaborate to develop and commercialize therapies for neurodegenerative diseases using Denali's Antibody Transport Vehicle…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda entered an option and collaboration agreement with Denali Therapeutics to develop and commercialize biologic products using Denali's Antibody Transport Vehicle (ATV) blood-brain barrier delivery technology for neurodegenerative diseases. The deal covered three programs: ATV:TREM2, ATV:BACE1/Tau, and a third undisclosed discovery-stage program. Takeda paid $40 million upfront, $5 million preclinical milestone, and $110 million in equity investment (~4.21M shares at ~$26.10/share). Total potential deal value up to $1.173 billion. The ATV:TREM2 program (DNL919) later received an FDA clinical hold and was subsequently discontinued.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. (this deal) | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2018 deals · Takeda Pharmaceutical Company Ltd. deals · Neurology deals